Navigation Links
Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
Date:3/31/2009

PRINCETON, N.J., March 31 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that dosing has started in a phase 1, single ascending dose (SAD) study in healthy volunteers with PSI-7851, a second generation nucleotide analog polymerase inhibitor of hepatitis C virus (HCV). Pharmasset filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) earlier this quarter.

"This is a significant milestone for Pharmasset. PSI-7851 is a wholly owned, second generation nucleotide analog that was discovered by Pharmasset scientists" stated Dr. Michelle Berrey, Pharmasset's Chief Medical Officer. "We continue to see nucleos(t)ide inhibitors as having the potential to be the cornerstone of future HCV treatment, given their higher barrier to resistance and antiviral activity across multiple HCV genotypes, characteristics that set them apart from other HCV drug classes. We look forward to reporting the first antiviral data with PSI-7851 in the second half of 2009."

About PSI-7851

PSI-7851 is a uridine nucleoside analog currently in developed for the treatment of chronic HCV infection. PSI-7851 has demonstrated in vitro anti-HCV activity with EC(50) values of 90 +/- 60 nM, which is approximately 15- to 20-fold more potent than the active metabolite of Pharmasset's first generation nucleoside polymerase inhibitor, R7128. In vitro studies of PSI-7851 have not shown evidence of any mitochondrial or other cellular toxicities that may be associated with some nucleoside analogs. The half-life of the triphosphate in primary human hepatocytes is approximately 38 hours, which suggests the possibility for once-daily dosing. Like R7128, PSI-7851 has demonstrated in vitro activity against all of the most common HCV genotypes.

About Pharmasset'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Reports Fiscal Year End 2008 Financial Results
2. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
3. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
4. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
5. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
6. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
7. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
8. Pharmasset Receives Notice of Allowance
9. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
10. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
11. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... LAGUNA HILLS, Calif. , July 30, 2015 ... developing nanoparticle drug delivery platforms, has received Orphan ... (FDA) for a second drug product that uses ... is a formulation of dactinomycin for the treatment ... bone cancer. The FDA granted NanoSmart,s Orphan Drug ...
(Date:7/30/2015)... , July 30, 2015  Arena Pharmaceuticals, Inc. (NASDAQ: ... conference call and webcast at 5:00 p.m. Eastern Time ... to discuss second quarter 2015 financial results and provide ... after the NASDAQ Global Select Market closes that day. ... dialing 877.643.7155 for domestic callers and 914.495.8552 for international ...
(Date:7/30/2015)... , July 30, 2015 EnteroMedics Inc. ... using neuroblocking technology to treat obesity, metabolic diseases and ... a conference call on Thursday, August 6, 2015, at ... the second quarter ended June 30, 2015, and to ... vBloc® Neurometabolic Therapy, delivered via the Maestro® System. ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 3
... July 28 Accuray Incorporated (Nasdaq: ARAY ), a global leader in ... quarter and fiscal year 2010, ended June 30, 2010 on Tuesday, ... , , ... / 5:00 p.m. ET and will be hosted by Euan S. Thomson ...
... , July 28 HemaQuest Pharmaceuticals, a ... sickle cell disease, beta thalassemia and EBV-related cancers, announced ... to its Series B financing by new investor, Latterell ... financing to $16M . The financing is intended ...
Cached Medicine Technology:Accuray Incorporated to Report Financial Results for Fourth Quarter and Fiscal Year 2010 2Accuray Incorporated to Report Financial Results for Fourth Quarter and Fiscal Year 2010 3Accuray Incorporated to Report Financial Results for Fourth Quarter and Fiscal Year 2010 4HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing 2
(Date:7/31/2015)... ... 2015 , ... Intellitec Solutions announced today they have expanded ... GP for a senior living facility in Maine. Having achieved recognition as a ... 16 states. This further expansion was again a factor of the firm’s success ...
(Date:7/30/2015)... ... , ... When responsible for the care of an aging loved one, summer ... mind: What happens if mom falls? Who will remind Dad to take his medications? ... But not taking time away from caregiving responsibilities can lead to bigger problems – ...
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... On July ... meeting in Manatee county to discuss plausible solutions for controlling the heroin outbreak. Ultimately ... event of an overdose is largely perpetuating the heroin crisis in North Florida. The ...
(Date:7/30/2015)... Austin, Texas (PRWEB) , ... July 30, 2015 ... ... Critical Path Institute (C-Path), and TransCelerate BioPharma, Inc. are pleased to announce that ... Dyslipidemia have been published for use on the CDISC website . These ...
(Date:7/30/2015)... ... July 30, 2015 , ... Women's dating coach Simone Myers ... for women interested in improving their love lives using specific "lines" designed to ... to the public early this morning, has drawn praise from several dating and ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2
... pigs has been identified by scientists in South Korea – ... //microbiology, following the findings of J.J. Shin and colleagues at ... pathogen, the H3N1 influenza A virus that can be found ... reassortment of influenza viruses. The virus, which was first identified ...
... a new treatment “target” to help millions of asthma ... research on certain white cells in the body that ... experienced by asthma patients. ,The scientists, at ... Cincinnati Children’s Hospital Medical Center, report their results in ...
... alert the antennae of call centre employees, and cause them ... call // centers in UK, who are now in a ... damage in their employees. This revelation is indeed a wake ... are undoubtedly risking an important faculty of theirs, gravely. , ...
... increase the chances of heart attack, but cocaine lifts the ... study reported that ‘while sex causes very little increased risk ... 20-folds’. ,The review by University of Sydney and ... attacks, including sexual activity, cocaine use, pollution, heavy meals, and ...
... has reached 80 with the recent death //of a 5-year ... non-governmental groups. It is believed that the five-year-old boy had ... ,Chief physician of the regional HIV/ AIDS prevention and ... that a child infected with HIV was registered in Turkestan, ...
... boards (DHBs) who ten days ago walked off their jobs, ... unresolved. // ,Anne Aitcheson, national co-ordinator of contingency planning ... back to normal at affected hospitals. ,She said, ... are booked and we will be back to normal." ...
Cached Medicine News:Health News:Scientists Pursue New Treatment For Asthma Sufferers 2Health News:Scientists Pursue New Treatment For Asthma Sufferers 3Health News:Radiographers Pay Parity Disputes Still Unresolved 2
Includes one aluminum pediatric eye shield and one eye garter shield cover. Packaged 50 per box. White only....
Non-linting, quick absorption and rounded corners. Tapered malleable handle. Dispenser carton contains 25 envelopes, each envelope contains 10 sponges packaged sterile in Tyvek peel-back pouch....
Straight, right side cutting, 1.5 mm x 4 mm bite, length of shaft 115 mm, overall length 6.3 inches....
Large: 22 x 25 mm, 0.9 x 1.0 inches. With holes. For support of the orbital rim following enucleation. Available in methylmethacrylate....
Medicine Products: